Julian S. Gangolli

Insider Reports History

Entity: Individual
Location: 4955 Baseline Avenue, Santa Ynez, CA
Signature: /s/ Krish Krishnan, as attorney-in-fact for Julian S. Gangolli
All insider transactions: Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Stock	Role	Class	Num Shares	Value	Price $	Report Date	Ownership
Revance Therapeutics, Inc.	Director	Common Stock	45.1K	$172K	$3.80	May 1, 2024	Direct
Krystal Biotech, Inc.	Director	Common Stock	0	$0	$165.76	May 20, 2024	Direct
Outlook Therapeutics, Inc.	Director	Stock Option (Right to Buy)	94.4K			Mar 7, 2024	Direct
Revance Therapeutics, Inc.	Director	Stock Option (Right to buy)	23.5K			May 1, 2024	Direct
Krystal Biotech, Inc.	Director	Stock Option (Right to Buy)	5K			Jun 30, 2024	Direct

Symbol	Company	Period	Transactions	Value $	Form Type	Date Filed	Role
KRYS	Krystal Biotech, Inc.	Jun 30, 2024	1	$0	4	Jul 1, 2024	Director
KRYS	Krystal Biotech, Inc.	May 20, 2024	5	-$2.83M	4	May 22, 2024	Director
RVNC	Revance Therapeutics, Inc.	May 1, 2024	2	$0	4	May 3, 2024	Director
OTLK	Outlook Therapeutics, Inc.	Mar 7, 2024	1	$0	4	Mar 8, 2024	Director
OTLK	Outlook Therapeutics, Inc.	Oct 4, 2023	1	$0	4	Oct 6, 2023	Director
KRYS	Krystal Biotech, Inc.	Jun 30, 2023	1	$0	4	Jul 3, 2023	Director
RVNC	Revance Therapeutics, Inc.	May 3, 2023	2	$0	4	May 5, 2023	Director
OTLK	Outlook Therapeutics, Inc.	Mar 29, 2023	1	$0	4	Mar 31, 2023	Director
OTLK	Outlook Therapeutics, Inc.	Oct 5, 2022	1	$0	4	Oct 7, 2022	Director
KRYS	Krystal Biotech, Inc.	Jun 30, 2022	1	$0	4	Jul 1, 2022	Director
RVNC	Revance Therapeutics, Inc.	May 4, 2022	1	$0	4/A	May 13, 2022	Director
OTLK	Outlook Therapeutics, Inc.	Mar 23, 2022	1	$0	4	Mar 24, 2022	Director
OTLK	Outlook Therapeutics, Inc.	Oct 5, 2021	1	$0	4	Oct 7, 2021	Director
KRYS	Krystal Biotech, Inc.	Jun 30, 2021	1	$0	4	Jul 2, 2021	Director
RVNC	Revance Therapeutics, Inc.	May 5, 2021	2	$0	4	May 7, 2021	Director